NCT01478347View on ClinicalTrials.gov

A Phase 3b Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered in Healthy At-risk Adults

PHASE3CompletedINTERVENTIONAL

Enrollment

18

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

March 31, 2014

Study Completion Date

November 30, 2014

Conditions

Meningococcal DiseaseMeningococcal Meningitis

Interventions

BIOLOGICAL

Recombinant meningococcal B + OMV NZ

2 injections 2 months apart

Trial Locations (1)

53100

UOC Medicina Interna 2, Azienda Ospedaliera Universitaria Senese, Siena

Sponsors

Lead Sponsor

Novartis Vaccines

Collaborators (1)

All Listed Sponsors

collaborator

Novartis

INDUSTRY

lead

Novartis Vaccines

INDUSTRY